Recombinant multi-species KMT2B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine KMT2B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a protein which contains multiple domains including a CXXC zinc finger, three PHD zinc fingers, two FY-rich domains, and a SET (suppressor of variegation, enhancer of zeste, and trithorax) domain. The SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. This gene is ubiquitously expressed in adult tissues. It is also amplified in solid tumor cell lines, and may be involved in human cancer. Two alternatively spliced transcript variants encoding distinct isoforms have been reported for this gene, however, the full length nature of the shorter transcript is not known. [provided by RefSeq, Jul 2008]
The Alternative Names of target: 2610014H22Rik,CXXC10,DYT28,HRX2,Histone-lysine N-methyltransferase 2B,KMT2B,Kmt2b,Lysine N-methyltransferase 2B,MLL1B,MLL2,MLL4,MRD68,Mll2,Mll4,Myeloid/lymphoid or mixed-lineage leukemia protein 4,RGD1308331,TRX2,Trithorax homolog 2,WBP-7,WBP7,WW domain-binding protein 7 (WBP-7),Wbp7,mKIAA0304

Target products collectionGo to KMT2B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP13905-Ag-1/ GM-Tg-hg-IP13905-Ag-2 Human KMT2B protein Human
GM-Tg-rg-IP13905-Ag-1/ GM-Tg-rg-IP13905-Ag-2 Rat KMT2B protein Rat
GM-Tg-mg-IP13905-Ag-1/ GM-Tg-mg-IP13905-Ag-2 Mouse KMT2B protein Mouse
GM-Tg-cynog-IP13905-Ag-1/ GM-Tg-cynog-IP13905-Ag-2 Cynomolgus/Rhesus macaque KMT2B protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP13905-Ag-1/ GM-Tg-felg-IP13905-Ag-2 Feline KMT2B protein Feline
GM-Tg-cang-IP13905-Ag-1/ GM-Tg-cang-IP13905-Ag-2 Canine KMT2B protein Canine
GM-Tg-bovg-IP13905-Ag-1/ GM-Tg-bovg-IP13905-Ag-2 Bovine KMT2B protein Bovine
GM-Tg-equg-IP13905-Ag-1/ GM-Tg-equg-IP13905-Ag-2 Equine KMT2B protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP13905-Ag-1/ GM-Tg-hg-IP13905-Ag-2; GM-Tg-rg-IP13905-Ag-1/ GM-Tg-rg-IP13905-Ag-2;
GM-Tg-mg-IP13905-Ag-1/ GM-Tg-mg-IP13905-Ag-2; GM-Tg-cynog-IP13905-Ag-1/ GM-Tg-cynog-IP13905-Ag-2;
GM-Tg-felg-IP13905-Ag-1/ GM-Tg-felg-IP13905-Ag-2; GM-Tg-cang-IP13905-Ag-1/ GM-Tg-cang-IP13905-Ag-2;
GM-Tg-bovg-IP13905-Ag-1/ GM-Tg-bovg-IP13905-Ag-2; GM-Tg-equg-IP13905-Ag-1/ GM-Tg-equg-IP13905-Ag-2
Products Name KMT2B protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name KMT2B
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine KMT2B protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.